View in EDS

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Authors: Burmester, Gerd R (AUTHOR), Buttgereit, Frank (AUTHOR), Bernasconi, Corrado (AUTHOR), Álvaro-Gracia, Jose M (AUTHOR), Castro, Nidia (AUTHOR), Dougados, Maxime (AUTHOR), Gabay, Cem (AUTHOR), van Laar, Jacob M (AUTHOR), Nebesky, Jan Michael (AUTHOR), Pethoe-Schramm, Attila (AUTHOR), Salvarani, Carlo (AUTHOR), Donath, Marc Y (AUTHOR), John, Markus R (AUTHOR), SEMIRA collaborators (CORPORATE AUTHOR)
Source: Lancet. 7/25/2020, Vol. 396 Issue 10246, p267-276. 10p.
Subjects: Therapeutic use of glucocorticoids, Therapeutic use of monoclonal antibodies, Glucocorticoids, Research, Combination drug therapy, Intravenous therapy, Oral drug administration, Research methodology, Monoclonal antibodies, Evaluation research, Medical cooperation, Drug administration, Comparative studies, Randomized controlled trials, Severity of illness index, Rheumatoid arthritis, Blind experiment, Prednisone, Disease remission, Subcutaneous injections
Geographic Terms: Russia, Italy, France, Serbia, Tunisia, Germany
Abstract: Background: Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised controlled trials to guide tapering of oral glucocorticoids is scarce. We investigated a scheme for tapering oral glucocorticoids compared with continuing low-dose oral glucocorticoids in patients with rheumatoid arthritis.Methods: The Steroid EliMination In Rheumatoid Arthritis (SEMIRA) trial was a double-blind, multicentre, two parallel-arm, randomised controlled trial done at 39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia). Adult patients with rheumatoid arthritis receiving tocilizumab and glucocorticoids 5-15 mg per day for 24 weeks or more were eligible for inclusion if they had received prednisone 5 mg per day for 4 weeks or more and had stable low disease activaity, confirmed by a Disease Activity Score for 28 joints-erythrocyte sedimentation rate (DAS28-ESR) of 3·2 or less 4-6 weeks before and on the day of randomisation. Patients were randomly assigned 1:1 to either continue masked prednisone 5 mg per day for 24 weeks or to taper masked prednisone reaching 0 mg per day at week 16. All patients received tocilizumab (162 mg subcutaneously every week or 8 mg/kg intravenously every 4 weeks) with or without csDMARDs maintained at stable doses during the entire 24-week study. The primary outcome was the difference in mean DAS28-ESR change from baseline to week 24, with a difference of more than 0·6 defined as clinically relevant between the continued-prednisone group and the tapered-prednisone group. The trial is registered with ClinicalTrials.gov, NCT02573012.Findings: Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77%] women and 59 [23%] men) were recruited onto the trial. In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08 (-0·27 to 0·12) with continued prednisone (difference 0·61 [0·35-0·88]; p<0·0001), favouring continuing prednisone 5 mg per day for 24 weeks. Treatment was regarded as successful (defined as low disease activity at week 24, plus absence of rheumatoid arthritis flare for 24 weeks and no confirmed adrenal insufficiency) in 99 (77%) patients in the continued-prednisone group versus 85 (65%) patients in the tapered-prednisone group (relative risk 0·83; 95% CI 0·71-0·97). Serious adverse events occurred in seven (5%) patients in the tapered-prednisone group and four (3%) patients in the continued-prednisone group; no patients had symptomatic adrenal insufficiency.Interpretation: In patients who achieved low disease activity with tocilizumab and at least 24 weeks of glucocorticoid treatment, continuing glucocorticoids at 5 mg per day for 24 weeks provided safe and better disease control than tapering glucocorticoids, although two-thirds of patients were able to safely taper their glucocorticoid dose.Funding: F Hoffmann-La Roche. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 145398422
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Burmester%2C+Gerd+R%22&quot;&gt;Burmester, Gerd R&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Buttgereit%2C+Frank%22&quot;&gt;Buttgereit, Frank&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bernasconi%2C+Corrado%22&quot;&gt;Bernasconi, Corrado&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22&#193;lvaro-Gracia%2C+Jose+M%22&quot;&gt;&#193;lvaro-Gracia, Jose M&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Castro%2C+Nidia%22&quot;&gt;Castro, Nidia&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dougados%2C+Maxime%22&quot;&gt;Dougados, Maxime&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gabay%2C+Cem%22&quot;&gt;Gabay, Cem&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22van+Laar%2C+Jacob+M%22&quot;&gt;van Laar, Jacob M&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Nebesky%2C+Jan+Michael%22&quot;&gt;Nebesky, Jan Michael&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pethoe-Schramm%2C+Attila%22&quot;&gt;Pethoe-Schramm, Attila&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Salvarani%2C+Carlo%22&quot;&gt;Salvarani, Carlo&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Donath%2C+Marc+Y%22&quot;&gt;Donath, Marc Y&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22John%2C+Markus+R%22&quot;&gt;John, Markus R&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22SEMIRA+collaborators%22&quot;&gt;SEMIRA collaborators&lt;/searchLink&gt; (CORPORATE AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. 7/25/2020, Vol. 396 Issue 10246, p267-276. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Therapeutic+use+of+glucocorticoids%22&quot;&gt;Therapeutic use of glucocorticoids&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Therapeutic+use+of+monoclonal+antibodies%22&quot;&gt;Therapeutic use of monoclonal antibodies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Glucocorticoids%22&quot;&gt;Glucocorticoids&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research%22&quot;&gt;Research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Combination+drug+therapy%22&quot;&gt;Combination drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Intravenous+therapy%22&quot;&gt;Intravenous therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Oral+drug+administration%22&quot;&gt;Oral drug administration&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research+methodology%22&quot;&gt;Research methodology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Monoclonal+antibodies%22&quot;&gt;Monoclonal antibodies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Evaluation+research%22&quot;&gt;Evaluation research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Medical+cooperation%22&quot;&gt;Medical cooperation&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Drug+administration%22&quot;&gt;Drug administration&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Comparative+studies%22&quot;&gt;Comparative studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Randomized+controlled+trials%22&quot;&gt;Randomized controlled trials&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Severity+of+illness+index%22&quot;&gt;Severity of illness index&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Rheumatoid+arthritis%22&quot;&gt;Rheumatoid arthritis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Blind+experiment%22&quot;&gt;Blind experiment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Prednisone%22&quot;&gt;Prednisone&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Disease+remission%22&quot;&gt;Disease remission&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Subcutaneous+injections%22&quot;&gt;Subcutaneous injections&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Russia%22&quot;&gt;Russia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Italy%22&quot;&gt;Italy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22France%22&quot;&gt;France&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Serbia%22&quot;&gt;Serbia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Tunisia%22&quot;&gt;Tunisia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Germany%22&quot;&gt;Germany&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: &lt;bold&gt;Background: &lt;/bold&gt;Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised controlled trials to guide tapering of oral glucocorticoids is scarce. We investigated a scheme for tapering oral glucocorticoids compared with continuing low-dose oral glucocorticoids in patients with rheumatoid arthritis.&lt;bold&gt;Methods: &lt;/bold&gt;The Steroid EliMination In Rheumatoid Arthritis (SEMIRA) trial was a double-blind, multicentre, two parallel-arm, randomised controlled trial done at 39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia). Adult patients with rheumatoid arthritis receiving tocilizumab and glucocorticoids 5-15 mg per day for 24 weeks or more were eligible for inclusion if they had received prednisone 5 mg per day for 4 weeks or more and had stable low disease activaity, confirmed by a Disease Activity Score for 28 joints-erythrocyte sedimentation rate (DAS28-ESR) of 3&#183;2 or less 4-6 weeks before and on the day of randomisation. Patients were randomly assigned 1:1 to either continue masked prednisone 5 mg per day for 24 weeks or to taper masked prednisone reaching 0 mg per day at week 16. All patients received tocilizumab (162 mg subcutaneously every week or 8 mg/kg intravenously every 4 weeks) with or without csDMARDs maintained at stable doses during the entire 24-week study. The primary outcome was the difference in mean DAS28-ESR change from baseline to week 24, with a difference of more than 0&#183;6 defined as clinically relevant between the continued-prednisone group and the tapered-prednisone group. The trial is registered with ClinicalTrials.gov, NCT02573012.&lt;bold&gt;Findings: &lt;/bold&gt;Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77%] women and 59 [23%] men) were recruited onto the trial. In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0&#183;54 (95% CI 0&#183;35-0&#183;73) with tapered prednisone and -0&#183;08 (-0&#183;27 to 0&#183;12) with continued prednisone (difference 0&#183;61 [0&#183;35-0&#183;88]; p&lt;0&#183;0001), favouring continuing prednisone 5 mg per day for 24 weeks. Treatment was regarded as successful (defined as low disease activity at week 24, plus absence of rheumatoid arthritis flare for 24 weeks and no confirmed adrenal insufficiency) in 99 (77%) patients in the continued-prednisone group versus 85 (65%) patients in the tapered-prednisone group (relative risk 0&#183;83; 95% CI 0&#183;71-0&#183;97). Serious adverse events occurred in seven (5%) patients in the tapered-prednisone group and four (3%) patients in the continued-prednisone group; no patients had symptomatic adrenal insufficiency.&lt;bold&gt;Interpretation: &lt;/bold&gt;In patients who achieved low disease activity with tocilizumab and at least 24 weeks of glucocorticoid treatment, continuing glucocorticoids at 5 mg per day for 24 weeks provided safe and better disease control than tapering glucocorticoids, although two-thirds of patients were able to safely taper their glucocorticoid dose.&lt;bold&gt;Funding: &lt;/bold&gt;F Hoffmann-La Roche. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=145398422
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(20)30636-X
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 267
    Subjects:
      – SubjectFull: Therapeutic use of glucocorticoids
        Type: general
      – SubjectFull: Therapeutic use of monoclonal antibodies
        Type: general
      – SubjectFull: Glucocorticoids
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Combination drug therapy
        Type: general
      – SubjectFull: Intravenous therapy
        Type: general
      – SubjectFull: Oral drug administration
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Monoclonal antibodies
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Drug administration
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Severity of illness index
        Type: general
      – SubjectFull: Rheumatoid arthritis
        Type: general
      – SubjectFull: Blind experiment
        Type: general
      – SubjectFull: Prednisone
        Type: general
      – SubjectFull: Disease remission
        Type: general
      – SubjectFull: Subcutaneous injections
        Type: general
      – SubjectFull: Russia
        Type: general
      – SubjectFull: Italy
        Type: general
      – SubjectFull: France
        Type: general
      – SubjectFull: Serbia
        Type: general
      – SubjectFull: Tunisia
        Type: general
      – SubjectFull: Germany
        Type: general
    Titles:
      – TitleFull: Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Burmester, Gerd R
      – PersonEntity:
          Name:
            NameFull: Buttgereit, Frank
      – PersonEntity:
          Name:
            NameFull: Bernasconi, Corrado
      – PersonEntity:
          Name:
            NameFull: Álvaro-Gracia, Jose M
      – PersonEntity:
          Name:
            NameFull: Castro, Nidia
      – PersonEntity:
          Name:
            NameFull: Dougados, Maxime
      – PersonEntity:
          Name:
            NameFull: Gabay, Cem
      – PersonEntity:
          Name:
            NameFull: van Laar, Jacob M
      – PersonEntity:
          Name:
            NameFull: Nebesky, Jan Michael
      – PersonEntity:
          Name:
            NameFull: Pethoe-Schramm, Attila
      – PersonEntity:
          Name:
            NameFull: Salvarani, Carlo
      – PersonEntity:
          Name:
            NameFull: Donath, Marc Y
      – PersonEntity:
          Name:
            NameFull: John, Markus R
      – PersonEntity:
          Name:
            NameFull: SEMIRA collaborators
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 07
              Text: 7/25/2020
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 396
            – Type: issue
              Value: 10246
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1